Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 1

Conditions

Neoplasms 3216Carcinoma, Non-Small-Cell Lung 2729Breast Neoplasms 2551Colorectal Neoplasms 1463Prostatic Neoplasms 1307Neoplasm Metastasis 1301Multiple Myeloma 1112Melanoma 1103Ovarian Neoplasms 1006Lung Neoplasms 945Recurrence 924Leukemia, Myeloid, Acute 879Pancreatic Neoplasms 833Lymphoma, Non-Hodgkin 767Lymphoma 713Stomach Neoplasms 692Carcinoma, Renal Cell 660Carcinoma, Hepatocellular 647Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 550Lymphoma, Follicular 515Head and Neck Neoplasms 490Glioblastoma 473Small Cell Lung Carcinoma 447Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 436Advanced Solid Tumors 432Leukemia 426Uterine Cervical Neoplasms 420Urinary Bladder Neoplasms 405

Interventions

Estriol 1Dehydroepiandrosterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Atrophic Vaginitis × Clear all
NCT01370551 2024-10-15

Gynoflor

Medinova AG

Phase 1 Completed
16 enrolled 20 charts

Atrophic Vaginitis

NCT03740945 2020-07-31

Effect of Intravaginal Prasterone on Symptoms of VVA in Women Under Treatment With an Aromatase Inhibitor for Breast Cancer

EndoCeutics Inc.

Phase 3 Withdrawn
Breast

Breast Neoplasms, Atrophic Vaginitis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡